



VIRUS FILTRATION EFFICIENCY TEST (VFE)
AT AN INCREASED CHALLENGE LEVEL

LABORATORY NUMBER:	193363
PROCEDURE NUMBER:	SOP/ARO/018D.1
SAMPLE SOURCE:	Pharma Systems AB
SAMPLE IDENTIFICATION:	Thermoflo 1 Filter/Pharma Mini, Art. No. 6100, Samples 1-4
DEVIATIONS:	None
DATA ARCHIVE LOCATION:	Sequentially by lab number
SAMPLE RECEIVED DATE:	27 Sep 2001
LAB PHASE START DATE:	10 Oct 2001
LAB PHASE COMPLETION DATE:	15 Oct 2001
REPORT ISSUE DATE:	16 Oct 2001
TOTAL NUMBER OF PAGES:	6

REFERENCE:

U.S. Department of Defense. 1975. MIL-M-36954C. Military Specification Mask, Surgical, Disposable.

INTRODUCTION:

This report describes the procedure and results of the virus filtration efficiency (VFE) testing. This procedure was performed to determine the filtration efficiency of the test materials using a ratio of the challenge to effluent to determine percent efficiency. This procedure allowed a reproducible aerosol challenge to be delivered to each of the test materials. This test procedure was modified from Nelson Laboratories, Inc., standard VFE test and employed a more severe challenge than would be expected in normal use.

JUSTIFICATION:

This VFE test provides a number of advantages over other filtration efficiency tests. The use of all glass impingers (AGIs) in the collection process allowed a high concentration of challenge to be delivered to each test material. The aerosol challenge particle size can be tightly controlled by monitoring the airflow and challenge flow through the nebulizer. The aerosol particles can be sized using a six-stage viable particle Andersen sampler.

All aerosols were contained so that there were no biosafety problems. The ϕ X174 bacteriophage has a diameter of 27 nm (0.027 μ m) and, therefore, provides a severe challenge to the test filter.

CHALLENGE PREPARATION:

A 100 mL aliquot of nutrient broth was inoculated with *Escherichia coli*, ATCC #13706, and incubated at $37 \pm 2^\circ\text{C}$ for 6-18 hours with rapid shaking. The culture was diluted 1:100, and incubated at $37 \pm 2^\circ\text{C}$. The culture was allowed to grow to a density of $2-4 \times 10^8$ CFU/mL. The bacterial culture was inoculated with the ϕ X174 bacteriophage stock culture (ATCC #13706-B1). The culture was incubated for 1-5 hours with rapid shaking. After complete *E. coli* lysis, the ϕ X174 phage culture was centrifuged, then filtered through a 0.2 μ m filter. The stock culture of ϕ X174 was kept at $2-8^\circ\text{C}$.

The challenge suspension was pumped through a 'Chicago' nebulizer using a peristaltic pump at a controlled flow rate and fixed air pressure. The constant challenge delivery at a fixed air pressure formed aerosol droplets of defined size. The challenge level was adjusted to provide a consistent challenge of greater than 10^6 plaque forming units per test sample.

The aerosol droplets were generated in a glass aerosol chamber and drawn through the sample holder and into all AGIs in parallel. Each AGI contained 30 mL aliquots of sterile PEPW to collect the aerosol droplets. The aerosol challenge flow rate was maintained at 30 Lpm.

The challenge was delivered for a 1 minute interval and sampling through the AGIs was conducted for 2 minutes to clear the aerosol chamber. Control runs (no media in sample holder) were performed after every 5-7 test samples to determine the number of viable particles being generated in the challenge aerosol. Test samples were ran by placing them into the sample holder, initiating challenge aerosol, and collection of effluent air into AGIs as with the controls.

The AGI fluid was assayed by placing aliquots of each sample into tubes containing 2.5 mL of top agar and 1-2 drops of *E. coli*. The contents were mixed and poured over the surface of the bottom agar plates. All plates were incubated at $37 \pm 2^\circ\text{C}$ for 17 hours.

The filtration efficiencies were calculated using the following equation:

$$\text{VFE \%} = \frac{\text{Plaques without filter} - \text{Plaques with filter}}{\text{Plaques without filter (Control)}} \times 100$$

STATEMENT OF UNCERTAINTY:

Due to the large number of data points available for the standard reference material used in the Viral Filtration Efficiency Test at Increased Challenge Level, the Type B Uncertainty factors have been determined to be incorporated into the Type A Uncertainty.

A statistical analysis of the VFE data resulted in the following:

Viral Filtration Efficiency (VFE) Mean @ 30 LPM = 99.94%
Standard Deviation = 0.12% VFE

The combined uncertainty for the VFE test @ 30 LPM is 0.015% VFE and the expanded uncertainty is 0.03% VFE at a confidence level of 95%.


It should be noted that the statistical analysis was conducted on data from Nelson Laboratories' standard reference material with a mean VFE @ 30 LPM of about 99.9%. It is expected that test materials submitted for VFE testing which have a VFE higher than 99.9% would have a combined uncertainty and an expanded uncertainty less than the uncertainty values reported here. Conversely, test materials with VFE values of less than 99.9% would be expected to yield a combined uncertainty and an expanded uncertainty greater than the uncertainty values reported here.

Test samples were not collected by the laboratory and therefore the representative nature of the samples is not included in the uncertainty assessment.

RESULTS:

The mean particle size (MPS) of the challenge aerosol was determined using a six-stage Andersen sampler and calculated to be 2.7 μm . The challenge level and filtration efficiencies of the samples are summarized in Table 1.


Quality Assurance Reviewer


Jeff Hills, B.S. SM(NRM)
Study Director

bdk



Study Completion Date

TABLE 1. VFE Results

SAMPLE IDENTIFICATION	CHALLENGE LEVEL (PFU)	TOTAL PFU RECOVERED	FILTRATION EFFICIENCY
Thermoflo 1 Filter/Pharma Mini, Art. NO. 6100, Sample 1	7.5×10^6	1.2×10^2	99.998%
Thermoflo 1 Filter/Pharma Mini, Art. NO. 6100, Sample 2	7.5×10^6	84	99.999%
Thermoflo 1 Filter/Pharma Mini, Art. NO. 6100, Sample 3	7.5×10^6	69	99.9991%
Thermoflo 1 Filter/Pharma Mini, Art. NO. 6100, Sample 4	7.5×10^6	60	99.9992%



Pharma Systems AB
Lab Number 193363

VFE at an Increased Challenge Level
Page 6

All reports and letters issued by Nelson Laboratories, Inc. are for the exclusive use of the sponsor to whom they are addressed. Reports may not be reproduced except in their entirety. No quotations from reports or use of the corporate name is permitted except as expressly authorized by Nelson Laboratories, Inc. in writing. The significance of any data is subject to the adequacy and representative character of the samples tendered for testing. Nelson Laboratories, Inc. warrants that all tests are performed in accordance with established laboratory procedures and standards. Nelson Laboratories, Inc. makes no other warranties of any kind, express or implied. Nelson Laboratories, Inc. expressly states that it makes no representation or warranty regarding the adequacy of the samples tendered for testing for any specific use of application, that determination being the sole responsibility of the sponsor. Nelson Laboratories' liability for any loss or damage resulting from its actions or failure to act shall not exceed the cost of tests performed, and it shall not be liable for any incidental or consequential damages.